BR112014025768A2 - métodos de tratamento de espondilite anquilosante usando antagonistas de il-17 - Google Patents

métodos de tratamento de espondilite anquilosante usando antagonistas de il-17

Info

Publication number
BR112014025768A2
BR112014025768A2 BR112014025768A BR112014025768A BR112014025768A2 BR 112014025768 A2 BR112014025768 A2 BR 112014025768A2 BR 112014025768 A BR112014025768 A BR 112014025768A BR 112014025768 A BR112014025768 A BR 112014025768A BR 112014025768 A2 BR112014025768 A2 BR 112014025768A2
Authority
BR
Brazil
Prior art keywords
methods
ankylosing spondylitis
patient
antagonists
treating ankylosing
Prior art date
Application number
BR112014025768A
Other languages
English (en)
Inventor
Brachat Arndt
Yelensky Roman
Bek Stephan
Hueber Wolfgang
Li Yali
Wang Ying
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014025768A2 publication Critical patent/BR112014025768A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

resumo patente de invenção: "métodos de tratamento de espondilite anquilosante usando antagonistas de il-17". a invenção refere-se a terapias personalizadas e métodos para o tratamento de espondilite anquilosante (as). especificamente, esta invenção se refere aos métodos de tratamento de um paciente tendo as administrando-se seletivamente um antagonista de il-17, por exemplo, um anticorpo il-17, tal como secukinumab, ao paciente de as com base no paciente ser predisposto ter uma resposta favorável ao tratamento com o antagonista de il-17. também descritos aqui são métodos diagnósticos e formas transmissíveis de informação úteis no prognóstico da probabilidade que um paciente tendo as responda ao tratamento com um antagonista de il-17, por exemplo, um anticorpo il-17, tal como secukinumab.
BR112014025768A 2012-04-20 2013-04-18 métodos de tratamento de espondilite anquilosante usando antagonistas de il-17 BR112014025768A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636062P 2012-04-20 2012-04-20
PCT/US2013/037068 WO2013158821A2 (en) 2012-04-20 2013-04-18 Methods of treating ankylosing spondylitis using il-17 antagonists

Publications (1)

Publication Number Publication Date
BR112014025768A2 true BR112014025768A2 (pt) 2017-07-04

Family

ID=48325883

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014025768A BR112014025768A2 (pt) 2012-04-20 2013-04-18 métodos de tratamento de espondilite anquilosante usando antagonistas de il-17

Country Status (13)

Country Link
US (1) US20150125462A1 (pt)
EP (1) EP2838560A2 (pt)
JP (1) JP2015519311A (pt)
KR (1) KR20150010709A (pt)
CN (1) CN104244979A (pt)
AR (1) AR090738A1 (pt)
AU (1) AU2013249232A1 (pt)
BR (1) BR112014025768A2 (pt)
CA (1) CA2870025A1 (pt)
MX (1) MX2014012640A (pt)
RU (1) RU2014146594A (pt)
TW (1) TW201347771A (pt)
WO (1) WO2013158821A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
EP3167892A1 (en) 2015-11-10 2017-05-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
IL297775A (en) * 2015-10-19 2022-12-01 Novartis Ag Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists
SG11201802887PA (en) 2015-10-27 2018-05-30 Ucb Biopharma Sprl Methods of treatment using anti-il-17a/f antibodies
CN111344043A (zh) * 2017-11-02 2020-06-26 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗肌腱病的方法
US11894121B2 (en) 2021-08-06 2024-02-06 Reviv Global Ltd Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods
US11600375B2 (en) 2021-07-30 2023-03-07 Reviv Global Ltd Genetically personalized food recommendation systems and methods

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
DK1963368T6 (da) 2005-12-13 2020-06-29 Lilly Co Eli Anti-il-17-antistoffer
KR20080099290A (ko) 2006-01-31 2008-11-12 노파르티스 아게 암 치료용 ｉｌ-17 길항 항체
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
UA103499C2 (ru) 2008-09-29 2013-10-25 Рош Глікарт Аг Антитело против интерлейкина-17 (ил-17) человека и его применение

Also Published As

Publication number Publication date
AR090738A1 (es) 2014-12-03
AU2013249232A1 (en) 2014-10-09
US20150125462A1 (en) 2015-05-07
CN104244979A (zh) 2014-12-24
WO2013158821A3 (en) 2014-03-13
CA2870025A1 (en) 2013-10-24
TW201347771A (zh) 2013-12-01
EP2838560A2 (en) 2015-02-25
RU2014146594A (ru) 2016-06-10
MX2014012640A (es) 2015-01-15
JP2015519311A (ja) 2015-07-09
WO2013158821A2 (en) 2013-10-24
KR20150010709A (ko) 2015-01-28

Similar Documents

Publication Publication Date Title
BR112014025768A2 (pt) métodos de tratamento de espondilite anquilosante usando antagonistas de il-17
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1119766T1 (el) Νεοι ρυθμιστες κινασης βενζοπυρανιου
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
SA517390092B1 (ar) مجالات تكرار أنكيرين مصمَّمة ذات نوعية ربط تجاه ألبومين مصل
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201590388A1 (ru) Способы лечения таупатии
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
EA201891142A1 (ru) Контроль клеточных окислительно-восстановительных уровней
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
UA109658C2 (xx) Антитіло проти cgrp
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
UA113712C2 (xx) Антитіло до fap і способи його застосування
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
BR112014031841A2 (pt) formulação farmacêutica
MX2014005183A (es) Anticuerpos anti-kdr y metodos de uso.
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)